Skip to main content
OpenTrials
Completed

NCT Number: NCT00377520

A Trial for Patients With Advanced/Recurrent Endometrial Cancer

The intent of this protocol is to screen a new agent for activity in patients with advanced or recurrent endometrial carcinoma. This phase II trial is studying how well pemetrexed disodium works in treating patients with advanced or recurrent endometrial carcinoma.

Completed

Looking for future studies?

Notify Me

Key information

Conditions

Neoplasms Cancer of Endometrium Cancer of the Endometrium Endometrial Cancer Endometrial Neoplasms Endometrium Cancer Female Urogenital Diseases Female Urogenital Diseases and Pregnancy Complications Genital Diseases Genital Diseases, Female Genital Neoplasms, Female Male Urogenital Diseases Neoplasms by Site Neoplasms, Endometrial Urogenital Diseases Urogenital Neoplasms Uterine Diseases Uterine Neoplasms

Sex eligibility

Female

Study type

Interventional

Phase

Phase 2

Primary location

Gynecologic Oncology Group 215-854-0770

Philadelphia, Pennsylvania, 19103, United States

Who can participate

Healthy volunteers accepted: No

Only the study team can determine whether someone qualifies for participation.

Inclusion criteria

  • Patients must have recurrent or persistent endometrial adenocarcinoma, which is refractory to curative therapy or established treatments.
  • Patients must have measurable disease.
  • Patients must have had one prior chemotherapeutic regimen for management of endometrial carcinoma.
  • Patients must have signed an approved informed consent.
  • Patients of childbearing potential must have a negative serum pregnancy test prior to the study entry and be practicing an effective form of contraception during the study and for at least 3 months following the last dose of Pemetrexed.
  • Patients must discontinue nonsteroidal anti-inflammatory (NSAIDs) medications 2-5 days prior to and for 1-2 days after receiving Pemetrexed, depending on the half-life of the NSAIDs treatment.
  • Patients must agree to this schedule in conjunction with every dose of Pemetrexed.
  • Patients must receive 350-1000 mcg of folic acid (e.g. one prenatal vitamin) starting 7 days prior to the first treatment with Pemetrexed.
  • Patients must be able to ingest 350-1000 mcg of folic acid daily until 3 weeks after the last dose of Pemetrexed.
  • Patients must receive 4 mg Dexamethasone by mouth twice daily, 1 day prior to the dose, the day of and the day after every dose of Pemetrexed.
  • Patients must receive a 1000 mcg vitamin B12 injection 7 days prior to receiving the first treatment with Pemetrexed.
  • Patients must agree to receive 1000 mcg vitamin B12 injection every 9 weeks until 3 weeks after the last dose of Pemetrexed.

Exclusion criteria

  • Patients who have had prior therapy with Pemetrexed
  • Patients who have received radiation to more than 25% of marrow bearing areas

Treatment and study plan

Pemetrexed

Drug

900 mg/m2, intravenous (IV), every 21 days, until disease progression

Other names: LY231514, Alimta

Primary outcomes

  1. Tumor Response

    Time frame: baseline to measured progressive disease (up to 24 months)

    Best response recorded from the start of treatment until disease progression/recurrence using Response Evaluation Criteria In Solid Tumors (RECIST) criteria that defines when participants improve ("respond"), stay the same ("stable"), or worsen ("progression") during treatment. Complete response (CR) = disappearance of all target lesions; Partial response (PR) = 30% decrease in the sum of the longest diameter of target lesions; Progressive disease (PD) = 20% increase in the sum of the longest diameter of target lesions; Stable disease (SD) = small changes that do not meet above criteria.

Secondary outcomes

  1. Number of Participants With Adverse Events by Grade (Measures of Toxicity)

    Time frame: every 21-day cycle (up to 24 months)

    Adverse events were graded using the Common Terminology Criteria for Adverse Events version 3.0 (CTCAE v3.0) for defining and grading specific adverse events. A grading (severity) scale is provided for each adverse event term. Grades range from 0 (none) to 5 (death). The worst grade event per cycle is reported.

Sponsors and collaborators

Lead sponsor

Eli Lilly and Company

Industry

Collaborators

  • Gynecologic Oncology Group

Registry information

Official study title

A Phase II Evaluation of Pemetrexed in the Treatment of Recurrent or Persistent Endometrial Carcinoma

Important dates

Study start
2006
Primary completion
2007
Study completion
2008
First posted
Sep 18, 2006
Registry last updated
Nov 20, 2009

OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.

View the official ClinicalTrials.gov record (opens in a new tab)

This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.

Related clinical trials

Published trials that share one or more normalized conditions with this study.